BioMed Research International / 2013 / Article / Tab 2

Review Article

Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 2

Pharmacologic properties of direct-acting anti-HCV agents in clinical development, modified by Liang and Ghany [71].

PropertyNS3-4A protease inhibitors

Genotypic coverageNarrow (second generation drugs have broader coverage)
Probability of drug resistanceHigh
Side effectsSubstantial
Drug-drug interactionsSubstantial

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.